Exalenz Debuts Rapid Urea Breath Test for Diagnosing H. Pylori

Share this content:

BreathID Hp, a new non-invasive urea breath test for diagnosing H. pylori, has been made available by Exalenz Bioscience. The test takes approximately 10–15 minutes to complete and deliver results, thus enabling the clinician to immediately prescribe treatment if necessary. This "test and treat" protocol has been recommended by the American College of Gastroenterology guideline.

BreathID Hp technology is based on measuring the level of change of 13C labeled urea detectable in a patient's breath. This is measured before and after the ingestion of a low dosage of 13C labeled urea dissolved in water or orange juice. Unlike other urea breath tests, BreathID Hp is performed in real-time. The patient's breath is sampled continuously and automatically, eliminating the need for sample collection, labeling, transport and analysis stages.

Helicobacter pylori (H. pylori), is a Gram-negative, microaerophilic bacterium found in the stomach and linked to the development of various digestive conditions as well as peptic ulcers and gastric cancer. According to reports, approximately 20% of people under 40 years old and half of adults over 60 years old in the U.S. are infected, with higher rates in developing countries.

For more information call (888)-EXALENZ or visit Exalenz.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs